1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin Cancer Res 2007, 13:170–181.
2. Arne G, Kristiansson E, Nerman O, Kindblom L-G, Ahlman H, Nilsson B, Nilsson O: Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int. J. Cancer 2011, 129:1149–1161.
3. Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Glabbeke MV, Debiec-Rychter M, Emile J-F, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouché O, Leyvraz S, Judson I, Verweij J, Casali P, Blay J-Y, Hohenberger P: Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clin Cancer Res 2012.
4. Chan F, Liu Y, Sun H, Li X, Shang H, Fan D, An J, Zhou D: Distribution and possible role of PDGF-AA and PDGFR-α in the gastrointestinal tract of adult guinea pigs. Virchows Archiv .
5. Daniels et al: Spectrum of KIT PDGFRA BRAF Mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in GIST Daniels Cancer Letters 312 (2011). Cancer Letters 2011, 312:43–54.
6. Gambacortipasserini C, Tornaghi L, Cavagnini F, Rossi P, Pecorigiraldi F, Mariani L, Cambiaghi N, Pogliani E, Corneo G, Gnessi L: Gynaecomastia in men with chronic myeloid leukaemia after imatinib. The Lancet 2003, 361:1954–1956.
7. Gasparotto D, Rossi S, Bearzi I, Doglioni C, Marzotto A, Hornick JL, Grizzo A, Sartor C, Mandolesi A, Sciot R, Debiec-Rychter M, Tos APD, Maestro R: Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity. Clin Cancer Res 2008, 14:5715–5721.
8. Heinrich MC, Griffith DJ, McKinley A, Patterson J, Presnell A, Ramachandran A, Debiec-Rychter M: Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-resistant Gastrointestinal Stromal Tumors. Clin Cancer Res 2012.
9. Jung SH, Suh KS, Kang DY, Kang DW, Kim Y-B, Kim E-S: Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal Tumors. Gut Liver 2011, 5:171–180.
10. Kwon JE, Kang HJ, Kim SH, Lee YC, Hyung WJ, Noh SH, Kim NK, Kim H: Pathological characteristics of gastrointestinal stromal tumours with PDGFRA mutations. Pathology 2009, 41:544–554.
11. Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB: Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers. Journal of Clinical Oncology 2009, 27:5262 –5269.
12. Pasini B, Matyakhina L, Bei T, Muchow M, Boikos S, Ferrando B, Carney JA, Stratakis CA: Multiple Gastrointestinal Stromal and Other Tumors Caused by Platelet-Derived Growth Factor Receptor   Gene Mutations: A Case Associated with a Germline V561D Defect. Journal of Clinical Endocrinology & Metabolism 2007, 92:3728–3732.
13. Reformulated imatinib eliminates morphine tolerance in lab studies [http://www.sciencecodex.com/reformulated_imatinib_eliminates_morphine_tolerance_in_lab_studies-86430].
Jerry Call
Author: Jerry Call